Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики
https://doi.org/10.47360/1995-4484-2021-367-383
Аннотация
В настоящее время получены веские доказательства фундаментальной роли патологической активации В-клеток в патогенезе иммуновоспалительных (аутоиммунных) ревматических заболеваний (ИВРЗ), а препараты, специфически модулирующие функцию или вызывающие истощение (depletion) различных субпопуляций В-клеток и плазматических клеток, рассматриваются как перспективное направление фармакотерапии этих заболеваний. Особый интерес представляет белимумаб (БЛМ) – человеческие моноклональные антитела (мАТ) (IgG1λ) к BAFF (B cell activating factor belonging to the TNF family), – который является первым «таргетным» генно-инженерным биологическим препаратом, специально разработанным для лечения системной красной волчанки (СКВ). Эффективность и безопасность БЛМ при СКВ у взрослых и детей, включая волчаночный нефрит, в комбинированной терапии с ритуксимабом, стероид-сберегающее действие, способность предотвращать необратимое поражение внутренних органов диктуют необходимость более широкого его применения в клинической практике.
Об авторах
Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)
Россия
Россия
115522, Российская Федерация, Москва, Каширское шоссе, 34а
119991, Российская Федерация, Москва, ул. Трубецкая, 8, стр. 2
Т. В. Попкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Российская Федерация, Москва, Каширское шоссе, 34а
А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия
Россия
115522, Российская Федерация, Москва, Каширское шоссе, 34а
125993, Российская Федерация, Москва, ул. Баррикадная, 2/1, стр. 1
Список литературы
1. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-199. doi: 10.1038/s41573-020-00092-2
2. Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. J Clin Invest. 2021;131(12):e149095. doi: 10.1172/JCI149095
3. Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5):539-548.
4. Насонов ЕЛ (ред.). Анти-В-клеточная терапия в ревматологии: Фокус на ритуксимаб. М.:ИМА-ПРЕСС;2012: 119-152.
5. Dörner T, Lipsky PE. Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol. 2016;12(11):645-657. doi: 10.1038/nrrheum.2016.158
6. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
7. Hamilton JA, Hsu HC, Mountz JD. Autoreactive B cells in SLE, villains or innocent bystanders? Immunol Rev. 2019;292(1):120-138. doi: 10.1111/imr.12815
8. Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614. doi: 10.1038/s41590-020-0677-6
9. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol. 2019;15(1):30-48. doi: 10.1038/s41584-018-0133-2
10. Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-2343. doi: 10.1016/S0140-6736(19)30237-5
11. Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14.
12. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272
13. Lever E, Alves MR, Isenberg DA. Towards precision medicine in systemic lupus erythematosus. Pharmgenomics Pers Med. 2020;13:39-49. doi: 10.2147/PGPM.S205079
14. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69-v81. doi: 10.1093/rheumatology/keaa403
15. Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076
16. Насонов ЕЛ, Решетняк ТМ, Денисов ЛН, Соловьев СК. Белимумаб: Прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;50(5):13-19.
17. Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones- Leone A, Rubin B, et al. 10 years of belimumab experience: What have we learnt? Lupus. 2021 Jul 8:9612033211028653. doi: 10.1177/09612033211028653
18. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/ APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-373. doi: 10.1038/nrrheum.2014.33
19. Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev. 2021;20(2):102736. doi: 10.1016/j.autrev.2020.102736
20. Eslami M, Schneider P. Function, occurrence and inhibition of different forms of BAFF. Curr Opin Immunol. 2021;71:75-80. doi: 10.1016/j.coi.2021.06.009
21. Супоницкая ЕВ, Александрова ЕН, Насонов ЕЛ. Клиническое значение BAFF/BLyS и APRIL при системной красной волчанке и ревматоидном артрите. Научно-практическая ревматология. 2014;52(5):545-552.
22. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190(11):1697-1710. doi: 10.1084/jem.190.11.1697
23. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995-999. doi: 10.1038/35010115
24. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthritis Rheum. 2001;44:1313-1319. doi: 10.1002/1529-0131(200106)44:6<1313::AIDART223> 3.0.CO;2-S
25. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003;48(12):3475-3486. doi: 10.1002/art.11354
26. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8:R6. doi: 10.1186/ar1855
27. Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem. 2006;39(12):1131-1137. doi: 10.1016/j.clinbiochem.2006.09.010
28. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-2459. doi: 10.1002/art.23678
29. Chu VT, Enghard P, Schürer S, Steinhauser G, Rudolph B, Riemekasten G, et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum. 2009;60(7):2083-2093. doi: 10.1002/art.24628
30. Zhao LD, Li Y, Smith MF Jr, Wang JS, Zhang W, Tang FL, et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus. 2010;19(13):1534-1549. doi: 10.1177/0961203310375268
31. McCarthy EM, Lee RZ, Ní Gabhann J, Smith S, Cunnane G, Doran MF, et al. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology (Oxford). 2013;52(7):1279-1284. doi: 10.1093/rheumatology/ket120
32. Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab. Lupus. 2016r;25(4):346-354. doi: 10.1177/0961203315604909
33. Howe HS, Thong BYH, Kong KO, Chng HH, Lian TY, Chia FL, et al. Associations of B cell-activating factor (BAFF) and anti- BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore. Clin Exp Immunol. 2017;189(3):298-303. doi: 10.1111/cei.12975
34. Friebus-Kardash J, Branco L, Ribi C, Chizzolini C, Huynh-Do U, Dubler D, et al. Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrol Dial Transplant. 2018;33(1):54-64. doi: 10.1093/ndt/gfx220
35. Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, et al. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunology. 2019;8(4):e01047. doi: 10.1002/cti2.1047
36. Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, et al. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: A post hoc meta-analysis. Arthritis Res Ther. 2020;22(1):102. doi: 10.1186/s13075-020-02177-0
37. Панафидина ТА, Сохова МА, Попкова ТВ, Черкасова МВ, Новиков АА, Александрова ЕН, и др. Клиническое значение концентраций лигандов BAFF и APRIL при системной красной волчанке. Научно-практическая ревматология.2016;54(2):145-154.
38. Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus. 2013;22(9):873-884. doi: 10.1177/0961203313496302
39. Marín-Rosales M, Cruz A, Salazar-Camarena DC, Santillán-López E, Espinoza-García N, Muñoz-Valle JF, et al. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med. 2019;19(2):183-190. doi: 10.1007/s10238-019-00549-8
40. Kang S, Fedoriw Y, Brenneman EK, Truong YK, Kikly K, Vilen BJ. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198(7):2602-2611. doi: 10.4049/jimmunol.1600281
41. Suso JP, Posso-Osorio I, Jiménez CA, Naranjo-Escobar J, Ospina FE, Sánchez A, et al. Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes. Lupus. 2018;27(5):708-715. doi: 10.1177/0961203317739132
42. Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2018;30(5):441-448. doi: 10.1097/BOR.0000000000000528
43. Kyaw T, Tipping P, Bobik A, Toh BH. Opposing roles of B lymphocyte subsets in atherosclerosis. Autoimmunity. 2017;50(1):52-56. doi: 10.1080/08916934.2017.1280669
44. Spinelli FR, Barbati C, Cecarelli F, Morello F, Colasanti T, Vomero M, et al. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):245. doi: 10.1186/s13075-019-2015-7
45. Saidoune F, Even G, Lamri Y, Chezel J, Gaston AT, Escoubet B, et al. Effects of BAFF neutralization on atherosclerosis associated with systemic lupus erythematosus. Arthritis Rheumatol. 2021;73(2):255-264. doi: 10.1002/art.41485
46. Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M, et al. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun. 2018;92:87-92. doi: 10.1016/j.jaut.2018.05.002
47. Depascale R, Gatto M, Zen M, Saccon F, Larosa M, Zanatta E, et al. Belimumab: A step forward in the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(5):563-573. doi: 10.1080/14712598.2021.1895744
48. Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of belimumab in treating immunemediated disorders. Allergy. 2020 Dec 26. doi: 10.1111/all.14704
49. Lamb YN. Belimumab in systemic lupus erythematosus: A profile of its use. Drugs Ther Perspect. 2021;37:1-12. doi: 10.1007/s40267-020-00788-w
50. Wei LQ, Liang YG, Zhao Y, Liang HT, Qin DC, She MC. Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: A meta-analysis. Clin Ther. 2016;38(5):1134-1140. doi: 10.1016/j.clinthera.2016.02.022
51. Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi: 10.1002/14651858.CD010668.pub2
52. Guzman M, Hui-Yuen JS. Management of pediatric systemic lupus erythematosus: Focus on belimumab. Drug Des Devel Ther. 2020;14:2503-2513. doi: 10.2147/DDDT.S216193
53. Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101
54. Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous Belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016-1027. doi: 10.1002/art.40049
55. Ahmed HM, Abohamad S, Elfishawi M, Hegazy MT, Vijaykumar K. Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: A critical review with focus on safety and satisfaction. Patient Prefer Adherence. 2018;12:2475-2479. doi: 10.2147/PPA.S147163
56. Poh YJ, Baptista B, D’Cruz DP. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration. Expert Rev Clin Immunol. 2017;13(10):925-938. doi: 10.1080/1744666X.2017.1371592
57. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al.; Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.doi: 10.1186/ar2506
58. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-78. doi: 10.1002/art.24699
59. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al.; BLISS-76 Study Group. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930. doi: 10.1002/art.30613
60. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi: 10.1016/S0140-6736(10)61354-2
61. Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus. J Drug Assess. 2013;2(1):40-48. doi: 10.3109/21556660.2013.792823
62. Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355-363. doi: 10.1136/annrheumdis-2017-211631
63. Ginzler E, Guedes Barbosa LS, D’Cruz D, Furie R, Maksimowicz-McKinnon K, et al.; At the time of the study. EMBRACE: Phase 3/4, randomized, 52-week study of belimumab efficacy and safety in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol. 2021 Jun 23. doi: 10.1002/art.41900
64. Sheikh SZ, Scheinberg MA, Cheng-Chung Wei J, Tegzova D, Stohl W, Acayaba de Toledo R, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021:e122-e130. doi: 10.1016/S2665-9913(20)30355-6
65. van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, et al. Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: Pooled analyses from the phase III belimumab trials. Arthritis Rheumatol. 2016;68(9):2184-2192. doi: 10.1002/art.39682
66. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-1838. doi: 10.1136/annrheumdis-2011-200831
67. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343-1349. doi: 10.1136/annrheumdis-2011-200937
68. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al.; BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65(8):2143-2153. doi: 10.1002/art.37995
69. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143-1151. doi: 10.1002/art.24698
70. Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al.; BLISS-52 and -76 Study Groups. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838-844. doi: 10.1136/annrheumdis-2012-202865
71. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, et al.; LBSL02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(2):300-309. doi: 10.3899/jrheum.121368
72. Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, et al.; LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(10):3364-73. doi: 10.1002/art.34564.
73. Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, et al. Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: A continuation of a seventy-six-week phase III parent study in the United States. Arthritis Rheumatol. 2018;70(6):868-877. doi: 10.1002/art.40439
74. Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(7):1125-1134. doi: 10.1002/art.40861
75. Tanaka Y, Bae SC, Bass D, Curtis P, Chu M, DeRose K, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 2021;7(2):e001629. doi: 10.1136/rmdopen-2021-001629
76. Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25(7):699-709. doi: 10.1177/0961203315625119
77. van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: A phase III study extension. Rheumatology (Oxford). 2020;59(2):281-291. doi: 10.1093/rheumatology/kez279
78. Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis. Ann Rheum Dis. 2019;78(3):372-379. doi: 10.1136/annrheumdis-2018-214043
79. Urowitz MB, Ohsfeldt RL, Wielage RC, Dever JJ, Zakerifar M, Asukai Y, et al. Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: A post hoc longitudinal study. Lupus Sci Med. 2020;7(1):e000412. doi: 10.1136/lupus-2020-000412
80. Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: Review of clinical studies. Patient Relat Outcome Meas. 2019;10:1-7. doi: 10.2147/PROM.S134326
81. Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: A post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1(1):e000031. doi: 10.1136/lupus-2014-000031
82. Scheinberg M, Golmia R. Real life experience on the effect of Belimumab in patients with active systemic lupus. Springer Plus. 2014;3:758. doi: 10.1186/2193-1801-3-758
83. Scheinberg MA, Golmia AP, Golmia RP, de Souza Molotievschi RN, Dos Santos Cortada AP. Lupus low disease activity (SLE) in patients treated with belimumab: A single-center real-life experience (2016–2019). Clin Rheumatol. 2021;40(3):923-927. doi: 10.1007/s10067-020-05315-w
84. Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S, et al. Belimumab for the treatment of refractory systemic lupus erythematosus: Real-life experience in the first year of use in 18 Italian patients. Isr Med Assoc J. 2014;16(10):651-653.
85. Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288-2295. doi: 10.3899/jrheum.150470
86. Sthoeger Z, Lorber M, Tal Y, Toubi E, Amital H, Kivity S, et al. Anti-BLyS treatment of 36 israeli systemic lupus erythematosus patients. Isr Med Assoc J. 2017;19(1):44-48.
87. Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(1):115-123. doi: 10.1002/acr.22971
88. Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017;16(4):343-351. doi: 10.1016/j.autrev.2017.02.005
89. Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, et al. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Semin Arthritis Rheum. 2018;48(3):467-474. doi: 10.1016/j.semarthrit.2018.02.014
90. Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1-8. doi: 10.1016/j.jaut.2017.09.004
91. Anjo C, Mascaró JM Jr, Espinosa G, Cervera R. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol. 2019;48(6):469-473. doi: 10.1080/03009742.2019.1603324
92. Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, et al. Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting. Arthritis Rheumatol. 2020;72(8):1314-1324. doi: 10.1002/art.41253
93. Cortés J, Andreu JL, Calvo J, García-Aparicio AM, Coronell CG, Díaz-Cerezo S. Evaluation of use of belimumab in clinical practice settings (observe study) in Spain: Health resource utilization and labour absenteeism. Value Health. 2014;17:A534. doi: 10.1016/j.jval.2014.08.1703
94. Collins CE, Dall’Era M, Kan H, Macahilig C, Molta C, Koscielny V, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3(1):e000118. doi: 10.1136/lupus-2015-000118
95. Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: Results from the OBSErve Germany Study. Rheumatol Ther. 2016;3:271-290. doi: 10.1007/s40744-016-0047-x
96. Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: Results from the OBSErve Canada Study. Rheumatol Int. 2017;37(6):865-873. doi: 10.1007/s00296-017-3682-9
97. von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger PM, Vallelian F, et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: A retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly. 2019;149:w20022.
98. Babini A, Garcia MA, Barreira JC, Pons-Estel B, Iglesias M, Streger G. Evaluation of use of belimumab in clinical practice settings: Results in Argentina. Arthritis Rheumatol. 2016;68(Suppl 10):1-4550.
99. Collins CE, Cortes-Hernández J, Garcia MA, von Kempis J, Schwarting A, Touma Z, et al. Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: Pooled analysis of multi-country data from the OBSErve studies. Rheumatol Ther. 2020;7(4):949-965. doi: 10.1007/s40744-020-00243-2
100. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. doi: 10.1038/s41572-019-0141-9
101. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089
102. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: A systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432-1441. doi: 10.1002/art.39594
103. Dooley MA, Houssiau F, Aranow C, D’Cruz DP, Askanase A, Roth DA, et al.; BLISS-52 and -76 Study Groups. Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63-72. doi: 10.1177/0961203312465781
104. Sciascia S, Radin M, Yazdany J, Levy RA, Roccatello D, Dall’Era M, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review. Autoimmun Rev. 2017;16(3):287-293. doi: 10.1016/j.autrev.2017.01.010
105. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180
106. Furie R, Rovin B, Houssiau F, Contreras G, Malvar A, Saxena A, et al. Effects of belimumab on renal outcomes, overall SLE control and biomarkers: Findings from a phase 3, randomized, placebocontrolled 104-week study in patients with active lupus nephritis [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10). URL: https://acrabstracts.org/abstract/effects-of-belimumab-on-renal-outcomes-overall-sle-control-and-biomarkers-findings-from-aphase-3-randomized-placebo-controlled-104-week-study-in-patients-with-active-lupus-nephritis (Accessed: 8th April 2021).
107. Margiotta DPE, Basta F, Batani V, Afeltra A. Belimumab and lowdoses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: Case series and literature review. BMC Nephrol. 2018;19(1):54. doi: 10.1186/s12882-018-0847-z
108. Dall’Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, et al. Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-1313. doi: 10.1002/art.39026
109. Hassan SU, Md Yusof MY, Emery P, Dass S, Vital EM. Biologic sequencing in systemic lupus erythematosus: After secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab. Front Med (Lausanne). 2020;7:498. doi: 10.3389/fmed.2020.00498
110. Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019;18(12):1133-1144. doi: 10.1080/14740338.2019.1685978
111. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, et al.; BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144-154. doi: 10.1177/0961203312469259
112. Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, et al.; BLISS-76 Study Group. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012;39(8):1632-1640. doi: 10.3899/jrheum.111587
113. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-210. doi: 10.1002/art.27189
114. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al.; BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328-2337. doi: 10.1002/art.34400
115. Ramsköld D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y, et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019;40:517-527. doi: 10.1016/j.ebiom.2018.12.035
116. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(5):1332-1342. doi: 10.1002/art.10949
117. Parodis I, Åkerström E, Sjöwall C, Sohrabian A, Jönsen A, Gomez A, et al. Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus. Int J Mol Sci. 2020;21(10):3463. doi: 10.3390/ijms21103463
118. Amend A, Wickli N, Schäfer AL, Sprenger DTL, Manz RA, Voll RE, et al. Dual role of interleukin-10 in murine NZB/W F1 lupus. Int J Mol Sci. 2021;22(3):1347. doi: 10.3390/ijms22031347
119. Facciotti F, Larghi P, Bosotti R, Vasco C, Gagliani N, Cordiglieri C, et al. Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus. Proc Natl Acad Sci USA. 2020;117(13):7305-7316. doi: 10.1073/pnas.1917834117
120. Arkatkar T, Du SW, Jacobs HM, Dam EM, Hou B, Buckner JH, et al. B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med. 2017;214(11):3207-3217. doi: 10.1084/jem.20170580
121. Kim SJ, Lee K, Diamond B. Follicular helper T cells in systemic lupus erythematosus. Front Immunol. 2018;9:1793. doi: 10.3389/fimmu.2018.01793
122. Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: Новые данные. Научно-практическая ревматология. 2019;57(4):452-461.
123. Rönnblom L, Leonard D. Interferon pathway in SLE: One key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. doi: 10.1136/lupus-2018-000270
124. Sjöstrand M, Johansson A, Aqrawi L, Olsson T, Wahren- Herlenius M, Espinosa A. The expression of BAFF is controlled by IRF transcription factors. J Immunol. 2016;196(1):91-96. doi: 10.4049/jimmunol.1501061
125. Regola F, Piantoni S, Lowin T, Archetti S, Reggia R, Kumar R, et al. Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with belimumab. Front Pharmacol. 2019;10:433. doi: 10.3389/fphar.2019.00433
126. Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70(8):1256-1264. doi: 10.1002/art.40511
127. Maslen T, Bruce IN, D’Cruz D, Ianosev M, Bass DL, Wilkinson C, et al. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: Post-hoc analysis of data from the phase III programme. Lupus Sci Med. 2021;8(1):e000459. doi: 10.1136/lupus-2020-000459
128. Petri M, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: A prospective study. J Rheumatol. 2009;36(11):2476-2480. doi: 10.3899/jrheum.090019
129. Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents. Front Med (Lausanne). 2020;7:303. doi: 10.3389/fmed.2020.00303
130. Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: Danger ahead? Nat Rev Rheumatol. 2016;12(6):367-372. doi: 10.1038/nrrheum.2016.18
131. Bela MM, Espinosa G, Cervera R. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus. 2021;30(1):134-140. doi: 10.1177/0961203320965707
132. Saito Y, Miyagawa Y, Onda K, Nakajima H, Sato B, Horiuchi Y, et al. B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology. 2008;125(4):570-590. doi: 10.1111/j.1365-2567.2008.02872.x
133. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2443-2457. doi: 10.1002/art.27515
134. Lin W, Seshasayee D, Lee WP, Caplazi P, McVay S, Suto E, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol. 2015;67(1):215-224. doi: 10.1002/art.38907
135. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2672-2679. doi: 10.1002/art.38074
136. Kawabata D, Venkatesh J, Ramanujam M, Davidson A, Grimaldi CM, Diamond B. Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. PLoS One. 2010;5(1):e8418. doi: 10.1371/journal.pone.0008418
137. Huang W, Quach TD, Dascalu C, Liu Z, Leung T, Byrne- Steele M, et al, Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight. 2018;3(17):e122525. doi: 10.1172/jci.insight.122525
138. van Dam LS, Osmani Z, Kamerling SWA, Kraaij T, Bakker JA, Scherer HU, et al. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. Rheumatology (Oxford). 2020;59(10):2734-2745. doi: 10.1093/rheumatology/kez623
139. Kraaij T, Huizinga TW, Rabelink TJ, Teng YK. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford). 2014;53(11):2122-2124. doi: 10.1093/rheumatology/keu369
140. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603. doi: 10.3389/fimmu.2017.00603
141. Manson JJ, Isenberg DA. The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. Expert Rev Clin Immunol. 2006;2(3):377-385. doi: 10.1586/1744666X.2.3.377
142. Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J, et al. Simultaneous detection of anti-C1q and antidouble stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares. Lupus. 2011;20(1):28-34. doi: 10.1177/0961203310379871
143. Thanei S, Vanhecke D, Trendelenburg M. Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways. Clin Immunol. 2015;160(2):180-187. doi: 10.1016/j.clim.2015.06.014
144. Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford). 2012;51(7):1208-1215. doi: 10.1093/rheumatology/ker526
145. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T; LJP 394 Investigator Consortium. Relationship between anti-double- stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(4):1129-1137. doi: 10.1002/art.20980
146. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54(3):723-732. doi: 10.1002/art.21650
147. Coremans IE, Spronk PE, Bootsma H, Daha MR, van der Voort EA, Kater L, et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis. 1995;26(4):595-601. doi: 10.1016/0272-6386(95)
148. Tipton CM, Hom JR, Fucile CF, Rosenberg AF, Sanz I. Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach. Immunol Rev. 2018;284(1):120-131. doi: 10.1111/imr.12660
149. Cheng Q, Mumtaz IM, Khodadadi L, Radbruch A, Hoyer BF, Hiepe F. Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis. 2013;72(12):2011-2017. doi: 10.1136/annrheumdis-2013-203455
150. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):3038-3047. doi: 10.1002/art.30466
151. Simonetta F, Allali D, Roux-Lombard P, Chizzolini C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84(2):235-236. doi: 10.1016/j.jbspin.2016.01.008
152. Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G. Rituximabrefractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016;34(2):355-356.
153. Gualtierotti R, Borghi MO, Gerosa M, Schioppo T, Larghi P, Geginat J, et al. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: A case series. Clin Exp Rheumatol. 2018;36(4):643-647.
154. Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003
155. Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2020 Jun 27:gfaa117. doi: 10.1093/ndt/gfaa117
156. Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, et al. Rituximab followed by belimumab controls severe lupus nephritis and bullous pemphigoid in systemic lupus erythematosus refractory to several combination therapies. Front Med (Lausanne). 2020;7:553075. doi: 10.3389/fmed.2020.553075
157. Shipa M, Embleton-Thirsk A, Parvaz M, Santos Ribeiro L, Muller P, Chowdhury K, et al. Belimumab after rituximab significantly reduced IgG anti-dsDNA antibody levels and prolonged time to severe flare in patients with systemic lupus erythematosus. Ann Rheum Dis. 2021;80:74. doi: 10.1136/annrheumdis-2021-eular.553
158. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73(1):121-131. doi: 10.1002/art.41466
159. Меснянкина АА, Соловьев СК, Александрова ЕН, Алексанкин АП, Асеева ЕА, Насонов ЕЛ. Двойная терапия генно-инженерными биологическими препаратами у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2016;54(3):281-309.
160. Меснянкина АА, Соловьев СК, Асеева ЕА, Насонов ЕЛ. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-309.
161. Mesnyankina A, Solovyev S, Aseeva E, Nikishina N. A rituximab and belimumab combination therapy in SLE patients. Ann Rheum Dis. 2020;79:1491. doi: 10.1136/annrheumdis-2020-eular
162. Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-1509. doi: 10.2215/CJN.01070118
163. Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol. 2015;16(7):755-765. doi: 10.1038/ni.3175
164. Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated tolllike receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49(4):725-739.e6. doi: 10.1016/j.immuni.2018.08.015
165. Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: A prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9(12):e032569. doi: 10.1136/bmjopen-2019-032569
166. Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9(3):e025687. doi: 10.1136/bmjopen-2018-025687
167. Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: Results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526-531. doi: 10.1136/annrheumdis-2013-203991
168. De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: The BELISS open-label phase II study. Rheumatology (Oxford). 2015;54(12):2249-2256. doi: 10.1093/rheumatology/kev257
169. Quartuccio L, Salvin S, Corazza L, Gandolfo S, Fabris M, De Vita S. Efficacy of belimumab and targeting of rheumatoid factor- positive B-cell expansion in Sjögren’s syndrome: Follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol. 2016;34(2):311-314.
170. Mariette X, Baldini C, Barone F, Bootsma H, Clark K, et al. Safety and efficacy of subcutaneous belimumab and intravenous rituximab combination in patients with primary Sjögren’s syndrome: A phase 2, randomised, placebo-controlled 68-week study. Ann Rheum Dis. 2021;80(Suppl 1):78.
171. Álvarez-Rivas N, Sang-Park H, Díaz Del Campo P, Fernández- Castro M, Corominas H, Andreu JL, et al. Efficacy of belimumab in primary Sjögren’s syndrome: A systematic review. Reumatol Clin (Engl Ed). 2021;17(3):170-174. doi: 10.1016/j.reuma.2020.03.003
172. Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, et al.; BREVAS Study Collaborators. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled study. Arthritis Rheumatol. 2019;71(6):952-963. doi: 10.1002/art.40802
173. McClure M, Gopaluni S, Wason J, Rosen AN, Henderson R, Salama A, et al. A randomised, double-blind, controlled, mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis (COMBIVAS): Study protocol. Rheumatology. 2019;58(Suppl 2). doi: 10.1093/rheumatology/kez063.046
174. Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol. 2013;40(5):579-589. doi: 10.3899/jrheum.120886
175. Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, et al.; BEL115123 Study Group. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323
176. Mahévas M, Azzaoui I, Crickx E, Canoui-Poitrine F, Gobert D, Languille L, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: Results from a prospective phase 2b trial. Haematologica. 2020 Aug 13. doi: 10.3324/haematol.2020.259481
177. Saadoun D, Ghembaza A, Riviere S, Mekinian A, Boutemy J, Leroux G, et al. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study. J Autoimmun. 2021;116:102577. doi: 10.1016/j.jaut.2020.102577
178. Yazici A, Yazirli B, Erkan D. Belimumab in primary antiphospholipid syndrome. Lupus. 2017;26(10):1123-1124. doi: 10.1177/0961203316682102
179. Klemm P, Müller-Ladner U, Tarner IH, Lange U, Hudowenz O. Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome. Autoimmun Rev. 2020;19(8):102594. doi: 10.1016/j.autrev.2020.102594
180. Barrett C, Willcocks LC, Jones RB, Tarzi RM, Henderson RB, Cai G, et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol Dial Transplant. 2020;35(4):599-606. doi: 10.1093/ndt/gfz086
181. Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X
182. Бекетова ТВ, Волков МЮ, Никонорова НО, Новоселова ТМ. Опыт эффективного применения комбинированной анти-В-клеточной терапии ритуксимабом и белимумабом при реф- рактерном гранулематозе с полиангиитом (Вегенера) с тяжелым поражением легких. Научно-практическая ревматология. 2017;55(1):104-109.
183. Насонов ЕЛ (ред.). Системная красная волчанка. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2019:113-114.
184. Mok CC, Hamijoyo L, Kasitanon N, Chen DY, Sheng Chen S, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet. 2021. doi: 10.1016/S2665-c99913(21)00009-6
Рецензия
Для цитирования:
Насонов Е.Л., Попкова Т.В., Лила А.М. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. https://doi.org/10.47360/1995-4484-2021-367-383
For citation:
Nasonov E.L., Popkova T.V., Lila A.M. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367-383. (In Russ.) https://doi.org/10.47360/1995-4484-2021-367-383
Просмотров: 2541
Послать статью по эл. почте 